Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COL10A1 small interfering RNA lentivirus
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
COL10A1 small interfering RNA lentivirus is an experimental gene therapy agent designed to silence the expression of the collagen type X alpha 1 chain (COL10A1). It utilizes a lentiviral vector to deliver small interfering RNA (siRNA) or short hairpin RNA (shRNA) that specifically targets and promotes the degradation of COL10A1 mRNA. COL10A1 is a member of the collagen family that is frequently overexpressed in various human cancers, including colorectal cancer (CRC), where it is associated with adverse prognosis and overall survival. By knocking down COL10A1, this agent inhibits tumor cell proliferation, migration, and invasion, and suppresses the epithelial-mesenchymal transition (EMT) process. Preclinical studies have demonstrated that knockdown of COL10A1 using this lentiviral construct can inhibit tumorigenesis in vivo, suggesting its potential as a therapeutic target for cancer treatment.
- Other names
- COL10A1 siRNA lentivirusCOL-10A1 siRNA lentivirusCOL 10A1 siRNA lentiviruslentiviral COL10A1 siRNAshCOL10A1 lentivirusshCOL-10A1 lentivirusshCOL 10A1 lentivirus
02
Targets
COL10A1
Beyond the preview
Go deeper on COL10A1 small interfering RNA lentivirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COL10A1 small interfering RNA lentivirus.